RecruitingPhase 2NCT05579639

Xylitol BSI Multisite - Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant

Reduction of Bloodstream Infections From Oral Organisms in Pediatric Stem Cell Transplant: a Randomized, Multicenter, Double-blind , Placebo-controlled Study Evaluating Twice Daily Oral Xylitol

Sponsor

Children's Hospital Medical Center, Cincinnati

Enrollment

419 participants

Start Date

Apr 4, 2023

Study Type

INTERVENTIONAL

Conditions

allogeneic stem cell transplantation

Summary

Bloodstream infections (BSI) caused by bacteria translocating across injured oral mucosa are a significant cause of morbidity and mortality in patients undergoing stem cell transplantation (SCT). Unfortunately, there are currently no known strategies to prevent these BSI in this vulnerable population. The investigators will conduct a randomized, double-blind, placebo-controlled trial at three institutions to evaluate the effectiveness of twice daily intraoral xylitol-wipe application on reducing BSI in pediatric SCT patients.

Eligibility

Min Age: 4 MonthsMax Age: 25 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Placebo and Xylitol for people with allogeneic stem cell transplantation. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 4 Months to 25 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.